A phase i trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization

Japanese Journal of Clinical Oncology

Volumn 38, Issue 4, 2008, Pages 268-274

  Miyanishi, Koji ^a   Ishiwatari, Hirotoshi ^a   Hayashi, Tsuyoshi ^a   Takahashi, Minoru ^a   Kawano, Yutaka ^a   Takada, Kohichi ^a   Ihara, Hideyuki ^a   Okuda, Toshinori ^a   Takanashi, Kunihiro ^a   Takahashi, Sho ^a   Sato, Yasushi ^a   Matsunaga, Takuya ^a   Homma, Hisato ^b   Kato, Junji ^a   Niitsu, Yoshiro ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Division of Gastroenterology   (Japan)

Author keywords

Chemo phase I II III; GI pancreas; GI pancreas med; GI pancreas radoncol; Radiology angio

Indexed keywords

FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HEMODYNAMICS; HUMAN; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PANCREAS BLOOD FLOW; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOEMBOLIZATION, THERAPEUTIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREATIC NEOPLASMS; PATIENT SELECTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 42549139014     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn015     Document Type: Article

References (23)

1. National Cancer Institute. Pancreatic cancer treatment (PDQ®): General information for health professionals. http://www.cancer.gov/cancertopics/pdq/treatment/pancreatic/ healthprofessional/
2. Burris HA, Moore MJ, Anderson J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefits with gemcitabine as first-line therapy for patients with advanced pancreatic cancer. J Clin Oncol 1997;15:2403-13.
3. Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999;17:585-92.
4. Berlin JD, Adak S, Vaughn DJ, Flinker D, Blaszkowsky L, Harris JE, et al. A phase II study of gemcitabine and 5-fluorourasil in metastatic pancreatic cancer: An Eastern Cooperative Oncology Group study (E3296). Oncology 2000;58:215-8.
5. Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002;20:1182-91.
6. Brodowicz T, Wolfram RM, Köstler WJ, Tomek S, Vaclavik I, Steger G, et al. Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anticancer Drugs 2000;11:623-8.
7. Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001;92:569-77.
8. Louvet C, André T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma; final results of a GERCOR multicenter phase II study. J Clon Onxol 2002;20:1512-8.
9. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E 2297. J Clin Oncol 2002;20:3270-5.
10. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83.
11. Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M. Fuchs, et al. A phase III trial of pametrexed plus gemcitabine versus gemcitabine in patients with unresctable or metastatic pancreatic cancer. Ann Oncol 2005;16:1639-45.
12. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-7.
13. Park JK, Ryu JK, Lee JK, Yoon WJ, Lee SH, Kim YT, et al. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. Pancreas 2006;33:397-402.
14. Ishida H, Makino T, Kobayashi M, Tsuneoka K. Laparoscopic measurement of pancreatic blood flow. Endoscopy 1983;15:107-10.
15. Homma H, Doi T, Mezawa S, Takada K, Kukitsu T, Oku T, et al. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer 1999;89:303-13.
16. Ikeda O, kusunoki S, kudoh K, Takamori H, Tsuji T, Kanemitsu K, et al. Evaluation of the efficacy of combined continuous arterial infusion and systemic chemotherapy for the treatment of advanced pancreatic carcioma. Cardiobasc Intervent Radiol 2006;29:362-70.
17. Klapdor R, Seutter E, Lang-Pölckow EM, Reichle H, Hinrichs. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simulataneous follow - up by imaging methods and tumor markers. Anticancer Res 1999;19:2459-70.
18. Grimison P, Galettis P, Manners S, Jelinek M, Metharom E, Souza PL, et al. Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: Evidence of auto-induction of gemcitabine accumulation. J Clin Oncol 2007;25:5704-9.
19. Shamseddine AI, Khalifeh MJ, Mourad FH, Chehal AA, Al-Kutoubi A, Abbas J, et al. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresctable pancreatic cancer patients. Clin Pharmacokinet 2005;44:657-7
20. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination of gemcitabine with fluorouracil versus gembitabine alone in patients with advanced pancreatic crcinoma: Eastern Cooperative Oncology Group Trial E J Clin Oncol 2002;20:3270-5.
21. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G. Gemcitabine alline or with cisplatin for the treatment of patients with locally advanced and/or metastatic ppancreatic carcinoma: A prospective, randomized phase III study of the Grupppo Oncologico dell' Italia Meridionale. Cancer 2002;94:902-10.
22. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat as first-line therapy for patients with unresctable pancreatic cancer: A randomized trial. J Clin Oncol 2001;19:3447-55.
23. Ikeda O, Tamura Y, Nakasone Y, Shiraishi S, Kawanaka K, Tomiguchi S, et al. Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma. Cardiovasc Intervent Radiol 2007;30:912-21.